Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson buys Specifar for €400mm to expand into Greece

Executive Summary

Strengthening its position in important European countries, Watson Pharmaceuticals Inc. (generics and branded women’s health products) has acquired private generic drug manufacturer Specifar Pharmaceuticals SA for €400mm ($562mm) in cash. Specifar stockholders may also receive up to €40mm in earn-outs related to the first five years of profits for the company’s generic proton pump inhibitor esomeprazole (AstraZeneca’s Nexium), which is awaiting approval and should be launched later this year in key European markets. The earn-outs will be based on sales in major territories in Europe, Asia, Latin America, and Canada.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract
    • Includes Earnout

Related Companies

Advertisement
UsernamePublicRestriction

Register